Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
HIV & AIDS
Do you routinely prescribe GLP-1 receptor agonists to people living with HIV (PLH) with obesity?
Nguyen Q, et al. PMID 38501237
Related Questions
Would you consider using long-acting injectable cabotegravir/rilpivirine for pregnant women with HIV?
How do you approach management for patient's with HIV on ART with persistent low level viremia but no new resistance mutations identified?
In what situations would you use "direct-to-inject" ART, such as Cabenuva, without an oral lead-in?
What is your approach to a positive PPD or IGRA in a patient with well-controlled HIV without significant TB risk factors?
Is there a role for routine LP in HIV patients with disseminated histoplasmosis even in the absence of CNS signs/symptoms?
What steps do you recommend to ensure continued viral suppression and prevent drug resistance in an HIV patient on injectable cabotegravir and rilpivirine who misses their scheduled injection appointment by two weeks?
What patient-specific factors would influence your decision to initiate semaglutide therapy in patients with HIV-associated lipohypertrophy?
What is your approach when cryptococcus serum or CSF antigen titers do not change despite treatment in HIV-positive patients with cryptococcal meningitis or invasive disease, but there is clinical improvement and cultures remain negative?
Would you recommend starting a moderate-intensity statin in a patient under the age of 40 years old with HIV and a 10-year ASCVD risk estimate below 5%?
How do you use CD4% in clinical practice in management of patients living with HIV?
